Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: Evaluation in comparison with mesothelin
Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: Evaluation in comparison with mesothelin
复制标题
DOI:
10.1016/j.lungcan.2008.02.012
复制
发表时间:
2008-10-01
期刊:
影响因子:
5.3
通讯作者:
Naka, Tetsuji
中科院分区:
文献类型:
--
作者:
Iwahori, Kota;Osaki, Tadashi;Naka, Tetsuji
Purpose: An early and reliable blood test is one deficiency in diagnosis of malignant pleural mesothelioma (MPM). Megakaryocyte potentiating factor (MPF) and mesothelin variants (MSLN), members of the mesothetin gene family, have been studied as candidate serum markers for MPM. We developed a novel enzyme-linked immunosorbent assay (ELISA) system to compare the diagnostic efficacy of MPF and MSLN in MPM and control groups.Experimental design: MPF and MSLN were assayed with ELISA in 27 consecutive MPM patients and 129 controls including patients with lung cancer and asymptornatic asbestos-exposed subjects.Results: Statistically significant elevation of serum MPF and MSLN levels was noted in MPM patients in comparison with every control group. The area under the receiver operating characteristic curve (AUC) was calculated for differentiation of MPM and lung cancer, healthy asbestos-exposed subjects, and healthy adults. While the AUC for serum MPF was 0.879, cutoff = 19.1 ng/ml (sensitivity = 74.1%, specificity = 90.4%), the AUC for serum MSLN was 0.713, cut-off = 93.5 ng/ml (sensitivity = 59.3%, specificity = 86.2%). Comparison between AUC for MPF and MSLN values shows that MPF is significantly superior to MSLN (p=0.025). Finally, there was a significant correlation between MPF and MSLN values for MPM (Pearson's correlation coefficient = 0.77; p< 0.001).Conclusions: These findings suggest that diagnostic value of MPF for MPM was better than that of MSLN although both markers showed almost equal specificity for MPM. (C) 2008 Elsevier Ireland Ltd. All rights reserved.